This essay has been submitted by a student. This is not an example of the work written by our professional essay writers.
We have a challenging and inspiring mission: to improve the quality of human life by enabling people to do more, feel better and live longer. This mission gives us the purpose to develop innovative medicines and products that help millions of people around the world.
We are one of the few pharmaceutical companies researching both medicines and vaccines for the World Health Organization's three priority diseases - HIV/AIDS, tuberculosis and malaria, and are very proud to have developed some of the leading global medicines in these fields.
As a leading international pharmaceutical company we make a real difference to global healthcare and specifically to the developing world. We believe this is both an ethical imperative and key to business success. Companies that respond sensitively and with commitment by changing their business practices to address such challenges will be the leaders of the future. GSK Pakistan operates mainly in two industry segments: Pharmaceuticals (prescription drugs and vaccines) and consumer healthcare (over-the-counter- medicines, oral care and nutritional care).
GSK leads the industry in value, volume and prescription market shares. We are proud of our consistency and stability in sales, profits and growth. Some of our key brands include Augmentin, Panadol, Seretide, Betnovate, Zantac and Calpol in medicine and renowned consumer healthcare brands include Horlicks, Aquafresh, Macleans and ENO.
In addition, GSK is deeply involved with our communities and undertake various Corporate Social Responsibility initiatives including working with the National Commission for Human Development (NCHD) for whom we were one of the largest corporate donors. We consider it our responsibility to nurture the environment we operate in and persevere to extend our support to our community in every possible way. GSK participates in year round charitable activities which include organizing medical camps, supporting welfare organizations and donating to/sponsoring various developmental concerns and hospitals. Furthermore, GSK maintains strong partnerships with non-government organizations such as Concern for Children, which is also extremely involved in the design, implementation and replication of models for the sustainable development of children with specific emphasis on primary healthcare and education.
In 1957 Glaxo started working in Pakistan.than in 1996 glaxo merged with Wellcome and became GlaxoWellcome.in year 2002 Wellcome acquired SmithKline French and beecham and company became GlaxoSmithKline.2 months back GSK has acquired the branded generics business of Bristol Myers Squibb (BMS) in Lebanon, Jordan, Syria, Libya and Yemen and also acquired Sirtris pharmaceuticals.
Partnering with the National Commission for Human Development for Primary Healthcare Extension:
GSK Pakistan has provided a grant of £144,000 sterling (Rs.12.96 million) to the NCHD "Primary Healthcare Extension Program" making GSK the largest corporate donor to this cause. The purpose of this grant is to contribute at the grass root level towards healthcare improvement of the Pakistani people. The great thing about the primary healthcare extension program is that it will be implemented in the areas generally recognized as difficult to access, hence often neglected due to harsh terrain, high levels of illiteracy and confined social setups.
Concern For Children Trust (CFC)
The Concern For Children Trust (CFC) is a non profit, non government trust established in 1997. Their mission is to promote the health and welfare of the Children of Pakistan, paying special attention to preventive and primary healthcare, education, infrastructure, maintenance and support and to create general awareness about various child healthcare issues. The Trust is partially self-sustainable in that, its operational costs are covered by a Trust Fund. SmithKline&French to SmithKline and French of Pakistan Limited donated the initial seed money and now GSK Pakistan continues to be the major donor.
International Programme for HIV Education "Positive Action Programme"
It is estimated that more than 36 million adults and children are living with HIV/AIDS with approximately 15,000 more people being infected each day. Globally, more than 21 million people have died from AIDS, resulting in 13.2 million orphaned children.
Positive Action is GSK's international programme of HIV education, care and community support. In this, GSK works in partnership with individuals, community groups, healthcare providers, international agencies and others to encourage HIV prevention as well as education, care and treatment of people living with, or affected by HIV/AIDS. Since its inception in 1992, positive action supported and implemented a wide variety of projects at both national and international levels throughout the world.
In this time of need and despair, GSK Pakistan was very quick to respond to the calamity affected areas with Rs. 20 million worth of antibiotics, analgesics and topical anti-bacterial supplies, delivered within 24 hours of the disaster having struck. Carefully selected emergency treatment packages were developed by the Crisis Management Team established, and a donation of up to 350,000 doses of Hepatitis A vaccine was given to health authorities to cope with the arising health concerns in the wake of the earthquake. This was all delivered within 24 hours of the disaster due to the urgent medical need.
PROGRAMMES AND OPPORTUNITIES TO ENCOURAGE ACTIVE EMPLOYEE INVOLVEMENT:
GSK encourages employees to become involved with deserving causes in their local communities around the globe.Â GSK support their time and dedication with various internal programmes and opportunities to encourage active employee involvement.
The PULSE Volunteer Partnership Programme is the newest corporate responsibility initiative. Starting in 2009, PULSE will empower GSK's high-performing employees to volunteer using their professional expertise, lasting for a period of three to six months. A PULSE volunteer will work full-time with one of our partner non-governmental organizations (NGO) to make a significant impact in impoverished communities around the world. With their skills and knowledge, PULSE volunteers will work to build positive, sustainable change within the NGO's programming and service delivery in developed and developing countries
ORANGE Day, introduced globally in January 2009, has enabled thousands of employees to make a significant difference through engaging with their local community.
Give as You Earn (GAYE), is a payroll giving scheme where an employee or pensioner can donate to any charitable organization in the UK, straight from their pay.
APPROACH TOWARD SOCIAL RESPONSIBILITY:
GSK has a proactive approach towards social responsibility. Managers at GSK actively participate and engage themselves in different social activities which include awareness regarding diseases, PULSE campaign, malaria, AIDS etc.
ABOUT GSK's CORPORATE ETHICS AND COMPLIANCE PROGRAMME
GSK's Corporate Ethics and Compliance Programme were established by the Board of Directors to support GSK's commitment to high standards of ethical conduct. The programme is under the direction of the Corporate Ethics and Compliance Officer, who reports to the Chief Executive Officer. Through the programme the Corporate Ethics and Compliance staff provides oversight and guidance to ensure compliance with applicable laws, regulations, and company policies, and to foster a positive, ethical work environment for all employees.
GSK's Code of Conduct is the foundation for all the company policies. It sets out the fundamental principles that the company values and that employees should apply in their daily work. Supporting the Code of Conduct policy is a range of corporate policies providing specific guidance in areas such as competition law, marketing practices, non-discrimination, share dealing, and conflicts of interest. GSK's employee guide to business conduct highlights the Code of Conduct, core compliance policies and provides guidance to employees. It is the responsibility of each employee to implement the code and follow the employee guide to sustain the trust and confidence of all GSK stakeholders. The six pages of code of conduct document clearly define the Purpose, scope, responsibilities, policies and communication of issues to all GSK employees. The policy covers the following function in GSK.
Competition from generic products generally occurs as patents in major markets expire. We believe that remaining competitive is dependent upon the discovery and development of new products, together with effective marketing of existing products. Within the pharmaceutical industry, the introduction of new products and processes by our competitors may affect pricing or result in changing patterns of product use. There is no assurance that products will not become outmoded, notwithstanding patent or trademark protection. In addition, increased government and other pressures for physicians and patients to use generic pharmaceuticals, rather than brand-name medicines, may increase competition for products that are no longer protected by patent.
The main customers of any pharmaceutical are the doctors. The brand name of GSK is so reliable that most of the doctors prefer only the GSK's product. GSK continuously spent money on R&D so to satisfy the customers need.
SUPPLIERS & DISTRIBUTORS:
Worldwide GSK buy goods and services from around 90,000 suppliers. Our supply chain is complex: it ranges from strategic relationships with suppliers that manufacture active pharmaceutical ingredients, intermediates, raw materials and packaging for GSK medicines to contracts for goods and services such as office equipment, cleaning and security. The Primary supply sites supply high quality, competitively priced bulk actives and focus on improvements in primary technologies and processes. GSK does not own any of the suppliers or distributors. New product and global supply sites work closely with R&D's development teams to ensure that the right technical competencies are in place to support rapid and successful new product